Drug Profile
Research programme: histone deacetylase inhibitors - Sulfidris
Alternative Names: ACS 2; ACS 33Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Sulfidris
- Class
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in Italy
- 17 Aug 2007 Preclinical trials in Prostate cancer in Italy (unspecified route)